drugset
drugset / Trial / NCT06947980

Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis

NCT06947980 ↗

Phase 2 Recruiting 200 enrolled Keymed Biosciences Co.Ltd
RandomizedParallel-groupTriple-blindTreatment

Summary

A Phase 2 study designed to evaluate the efficacy and safety of CM512 in adult patients with moderate-to-severe Atopic Dermatitis (AD).

Timeline

Start
2025-06-19
Primary completion
2026-07-18
Completion
2026-11-07

Drugs

EvaluationDrugModalityDoseRoute
Subject CM512 Unknown — Subcutaneous

Indications

atopic eczema